Wednesday, July 8, 2026

Patent intelligence · US

US 11229606

Extended release compositions comprising pyridostigmine

granted A61KA61K31/4425A61K9/0065A61K9/2846
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 16
Applicant portfolio 32
Patent details — US 11229606
Jurisdiction
US
Status
granted
Grant date
Jan 25, 2022
Expiration
Jan 20, 2042
Claims
18
CPC classes
A61K, A61K31/4425, A61K9/0065, A61K9/2846
View on Google Patents ↗

Quick answer

US 11229606 (Extended release compositions comprising pyridostigmine) is held by Amneal Complex Products Research LLC. Status: granted. Granted Jan 25, 2022. Expires Jan 20, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
18
CPC classes
A61K, A61K31/4425, A61K9/0065, A61K9/2846, A61K9/2866, A61K9/2886

More from Amneal Complex Products Research LLC

Related pharmaceutical patents in our USPTO index.

  1. US 12383522

    Baclofen formulations and methods of minimizing patient exposure to metabolite variations

    AMNEAL PHARMACEUTICALS LLC · Expires Aug 7, 2045

    granted
  2. US 12370163

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Expires Jul 24, 2045

    granted
  3. US 12303482

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Expires May 15, 2045

    granted
  4. US 12303481

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Expires May 15, 2045

    granted
  5. US 12295931

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Expires May 8, 2045

    granted
  6. US 12263149

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Expires Mar 27, 2045

    granted
  7. US 12263148

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Expires Mar 27, 2045

    granted
  8. US 12233166

    Extended release compositions comprising pyridostigmine

    Amneal Complex Products Research LLC · Expires Feb 20, 2045

    granted

Frequently asked questions

What is US patent 11229606?

US 11229606 (Extended release compositions comprising pyridostigmine) is held by Amneal Complex Products Research LLC. Status: granted. Granted Jan 25, 2022. Expires Jan 20, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11229606?

Amneal Complex Products Research LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 32 pharmaceutical patents for this assignee.

When does US 11229606 expire?

Our index shows an expiration date of Jan 20, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.